Hydroxynitrile Lyase Market

Hydroxynitrile Lyase Market Analysis and Forecast by Fact.MR

• The Hydroxynitrile Lyase Market is expected to grow from USD 129.1 million in 2026 to USD 268.6 million by 2036, at a 7.6% CAGR.
•  driven by expanding pharmaceutical adoption of biocatalytic synthesis for chiral intermediates, growing preference for enzymatic processes over chemical catalysis in green chemistry manufacturing, and advancing recombinant enzyme engineering improving activity, stability, and substrate scope, with recombinant enzymes accounting .
• 44.8% share and pharmaceutical companies contributing 63.2% share as manufacturers prioritize enantioselective synthesis efficiency, regulatory compliance, and process sustainability.

Summary of Hydroxynitrile Lyase Market

• Market Snapshot
  • In 2025, the global Hydroxynitrile Lyase Market was valued at approximately USD 120.0 million.
  • The market is estimated to reach USD 129.1 million in 2026 and is projected to attain USD 268.6 million by 2036.
  • The hydroxynitrile lyase market is likely to expand at a CAGR of 7.6% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 139.5 million between 2026 and 2036.
  • Recombinant hydroxynitrile lyase enzymes account for 44.8% of product segment share in 2026.
  • China (10.2%) and India (9.5%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Pharmaceutical industry adoption of biocatalytic synthesis routes for chiral intermediate production is the primary driver, as hydroxynitrile lyases enable enantioselective cyanohydrin formation with higher stereoselectivity and milder reaction conditions than traditional chemical catalysis.
  • Green chemistry regulatory and corporate sustainability mandates are encouraging pharmaceutical manufacturers to replace stoichiometric metal catalysts and hazardous solvents with enzymatic processes that generate less waste and operate under ambient conditions.
  • Advancing recombinant enzyme engineering using directed evolution and computational protein design is expanding the substrate scope, thermostability, and volumetric productivity of hydroxynitrile lyases, making biocatalytic routes commercially viable for a broader range of pharmaceutical and fine chemical intermediates.
  • Growing contract development and manufacturing organization (CDMO) adoption of biocatalytic capabilities is expanding access to hydroxynitrile lyase technology for pharmaceutical companies that lack in-house enzyme screening and process development infrastructure.
• Product and Segment View
  • Recombinant hydroxynitrile lyase enzymes account for 44.8% of the product segment in 2026, supported by their superior activity, consistency, and scalability compared to plant-extracted enzyme preparations that suffer from batch variability and limited substrate flexibility.
  • Pharmaceutical companies represent 63.2% of end-use demand in 2026, reflecting the concentration of hydroxynitrile lyase procurement among drug manufacturers producing chiral intermediates for cardiovascular, antiviral, and central nervous system therapeutic programs.
  • Liquid enzyme formulations lead the formulation segment with 68.4% share in 2026, as liquid preparations offer easier handling, dosing, and integration into existing reactor systems at pharmaceutical manufacturing scale.
  • Key segmentation includes:
    • Product Type: Recombinant Hydroxynitrile Lyase Enzymes, Plant-Extracted Enzyme Preparations, Immobilized Enzyme Systems, Engineered Variant Libraries
    • End Use: Pharmaceutical Companies, Fine Chemical Manufacturers, Agrochemical Producers, Contract Research Organizations
    • Formulation: Liquid Enzyme Formulations, Lyophilized Powder Preparations, Immobilized Solid Formulations
  • These systems enable:
    • Enantioselective cyanohydrin synthesis from aldehydes and ketones with enantiomeric excess typically exceeding 95%, enabling production of chiral building blocks for pharmaceutical intermediate synthesis.
    • Ambient temperature and aqueous reaction conditions that eliminate the need for cryogenic cooling, anhydrous solvents, and hazardous metal catalysts required by traditional chemical cyanohydrin synthesis.
    • Scalable biocatalytic process from milligram screening through kilogram manufacturing with consistent stereoselectivity, supporting pharmaceutical development from early discovery through commercial production.
• Geography and Competitive Outlook
  • Europe leads the market, supported by established pharmaceutical biocatalysis infrastructure in Germany (8.8%), Switzerland, and the Netherlands, enzyme producer concentration, and EU green chemistry regulatory support.
  • Asia Pacific is the fastest-growing region, with China (10.2%) and India (9.5%) expanding through pharmaceutical manufacturing growth, CDMO biocatalysis capability investment, and increasing fine chemical production for global pharmaceutical supply chains.
  • North America maintains a significant share, with US pharmaceutical companies and CDMOs adopting biocatalytic routes for chiral intermediate production, supported by Codexis and other enzyme engineering platform companies.
  • Novozymes (DSM-Firmenich), c-LEcta, Codexis, Enzymaster, Evonik Industries, BASF, Johnson Matthey, and Almac Group are among the key companies.
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The hydroxynitrile lyase market sits at the intersection of two powerful trends: pharmaceutical green chemistry adoption and enzyme engineering technology maturation. Ten years ago, enzymatic cyanohydrin synthesis was a laboratory curiosity. Today, recombinant enzyme engineering has produced variants with sufficient activity and stability for commercial pharmaceutical manufacturing. The market is still in early commercial scaling, with the most significant growth opportunity coming from CDMO adoption that makes biocatalytic capability accessible to smaller pharmaceutical companies without in-house enzyme development resources.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Pharmaceutical industry green chemistry commitments are creating procurement preference for enzymatic synthesis routes that replace hazardous metal catalysts and organic solvents with biocatalytic processes operating under mild aqueous conditions, reducing environmental waste and improving worker safety.
• Recombinant enzyme engineering breakthroughs using directed evolution and computational protein design have expanded the practical substrate scope and thermal stability of hydroxynitrile lyases, making biocatalytic cyanohydrin synthesis commercially viable for pharmaceutical manufacturing scale.
• CDMO investment in biocatalysis capabilities is democratizing access to enzymatic synthesis, enabling small and mid-size pharmaceutical companies to adopt hydroxynitrile lyase processes through outsourced manufacturing without building in-house enzyme development infrastructure.

Key Market Constraints

• Enzyme development timelines of 6 to 18 months for new substrate optimization limit adoption speed for pharmaceutical programs with compressed development schedules, as chemical catalysis routes can often be implemented faster from known literature precedents.
• Production cost of engineered recombinant enzymes remains higher than commodity chemical catalysts on a per-reaction basis, creating a cost barrier for high-volume fine chemical applications where stereoselectivity requirements do not justify the enzymatic premium.
• Intellectual property complexity around engineered enzyme variants and their associated production organisms creates licensing and freedom-to-operate considerations that can complicate manufacturing scale-up and supplier diversification for pharmaceutical customers.

Key Opportunity Areas

• Expanding the biocatalytic toolbox through multi-enzyme cascade reactions that combine hydroxynitrile lyases with downstream enzymatic transformations is enabling more complex chiral intermediate synthesis in fewer steps, reducing manufacturing cost and waste.
• AI-driven enzyme engineering that uses machine learning to predict beneficial mutations is accelerating the development of improved hydroxynitrile lyase variants, reducing the time and cost of enzyme optimization for new pharmaceutical substrate targets.
• Growing pharmaceutical outsourcing to CDMOs in India and China is creating demand for biocatalytic capability investment at contract manufacturing facilities serving global pharmaceutical supply chains.

Segment-wise Analysis of the Hydroxynitrile Lyase Market

• Recombinant hydroxynitrile lyase enzymes hold 44.8% of the product segment in 2026, supported by superior consistency, scalability, and substrate flexibility compared to plant-extracted preparations.
• Pharmaceutical companies account for 63.2% of end-use demand in 2026, driven by chiral intermediate production requirements for cardiovascular, antiviral, and CNS therapeutic programs.
• Immobilized enzyme systems are the fastest-growing formulation type, as immobilization enables enzyme reuse across multiple reaction cycles, improving process economics for high-volume pharmaceutical manufacturing applications.

The hydroxynitrile lyase market is segmented by product type, end use, formulation, and region. By product type, the market covers recombinant enzymes, plant-extracted preparations, immobilized systems, and engineered variant libraries. By end use, coverage includes pharmaceutical companies, fine chemical manufacturers, agrochemical producers, and CROs. Recombinant enzymes lead by value due to their performance advantages, while immobilized formulations represent the highest growth format.

Which Product Segment Dominates the Hydroxynitrile Lyase Market?

Recombinant hydroxynitrile lyase enzymes account for 44.8% of the product segment in 2026. Their leadership reflects the advantages of recombinant production in delivering consistent enzyme quality, higher specific activity, and broader substrate scope compared to plant-extracted preparations. Recombinant enzymes produced in bacterial or yeast expression systems can be engineered for specific substrate preferences and operational conditions, making them the preferred choice for pharmaceutical manufacturing applications.

Plant-extracted preparations hold a supporting position, primarily serving academic research and early-stage screening applications where cost and enzyme availability are prioritized over the optimization and consistency that recombinant systems provide for manufacturing scale.

Which End-Use Segment Dominates the Hydroxynitrile Lyase Market?

Pharmaceutical companies are expected to lead the end-use segment with a 63.2% share in 2026. This dominance reflects the concentration of chiral intermediate demand in pharmaceutical manufacturing, where hydroxynitrile lyase-catalyzed cyanohydrin synthesis provides enantioselective access to chiral building blocks used in the production of cardiovascular drugs, antiviral agents, and central nervous system therapeutics.

Fine chemical manufacturers and CDMOs hold growing positions, serving pharmaceutical customers through outsourced biocatalytic manufacturing services. The CDMO channel is expanding rapidly as smaller pharmaceutical companies adopt enzymatic synthesis through contract manufacturing rather than building in-house biocatalysis capability.

Which Technology Trend is Shaping the Next Phase of Growth in the Hydroxynitrile Lyase Market?

AI-driven enzyme engineering is the most significant technology trend shaping the hydroxynitrile lyase market. Machine learning models trained on protein structure and function data can predict beneficial mutations that improve enzyme activity, thermostability, and substrate acceptance with significantly fewer experimental iterations than traditional directed evolution approaches. This reduces enzyme development timelines from 12 to 18 months to 3 to 6 months for new substrate optimization, accelerating the adoption of biocatalytic routes in pharmaceutical programs with compressed development schedules.

The convergence of AI-driven enzyme engineering with automated high-throughput screening platforms is creating a step change in the speed and cost of developing new hydroxynitrile lyase variants for specific pharmaceutical targets. Companies including Codexis and Enzymaster that combine computational prediction with experimental validation infrastructure are positioned to capture the value created by faster enzyme optimization cycles.

Regional Outlook Across Key Markets

• China leads growth at 10.2%, driven by pharmaceutical manufacturing expansion, CDMO biocatalysis investment, and growing fine chemical production for global pharmaceutical supply chains.
• India follows at 9.5%, supported by pharmaceutical manufacturing growth under PLI incentives, CDMO capability development, and increasing adoption of biocatalytic processes at domestic API production facilities.
• Germany leads European growth at 8.8%, supported by established pharmaceutical biocatalysis infrastructure, c-LEcta and Evonik enzyme production capabilities, and EU green chemistry regulatory support.
• North America maintains a significant share, with Codexis enzyme engineering platform and US pharmaceutical company biocatalysis adoption driving demand.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Hydroxynitrile Lyase Demand Trends in the United States

The US hydroxynitrile lyase market is projected to grow at a CAGR of 6.2% through 2036. Pharmaceutical company adoption of biocatalytic synthesis routes and Codexis enzyme engineering platform capability are the primary demand drivers. FDA green chemistry guidance supporting enzymatic process adoption in pharmaceutical manufacturing provides regulatory alignment, while CDMO biocatalysis investment at US contract manufacturing facilities expands enzyme process accessibility for smaller pharmaceutical programs.

• Codexis enzyme engineering platform provides US pharmaceutical companies with optimized hydroxynitrile lyase variants for specific chiral intermediate production targets.
• FDA green chemistry guidance supports pharmaceutical manufacturer adoption of enzymatic synthesis routes that reduce hazardous waste and improve process safety profiles.

China Hydroxynitrile Lyase Growth Assessment

Pharmaceutical manufacturing expansion and CDMO biocatalysis capability investment are creating growing demand for hydroxynitrile lyase enzymes in China. Enzymaster and other domestic enzyme engineering companies are developing local production and optimization capability, reducing import dependency for pharmaceutical biocatalyst supply. Growing fine chemical production for global pharmaceutical supply chains creates additional demand for enantioselective biocatalytic processes at Chinese manufacturing facilities.

• Domestic enzyme engineering companies including Enzymaster are building local hydroxynitrile lyase optimization and production capability for pharmaceutical customers.
• CDMO biocatalysis investment at Chinese contract manufacturing facilities creates demand for enzymatic synthesis capability serving global pharmaceutical supply chains.

India Hydroxynitrile Lyase Market Opportunity Outlook

PLI-backed pharmaceutical manufacturing expansion and India growing position as a global API production hub are creating demand for biocatalytic process capabilities at domestic manufacturing facilities. The adoption of enzymatic synthesis routes by Indian pharmaceutical companies and CDMOs is increasing as green chemistry requirements from Western pharmaceutical customers flow through contract manufacturing supply chain specifications.

• PLI-backed pharmaceutical manufacturing creates demand for advanced biocatalytic capabilities including hydroxynitrile lyase processes at Indian API production facilities.
• Western pharmaceutical customer green chemistry requirements are driving biocatalysis adoption at Indian CDMO facilities serving global drug development programs.

Germany Hydroxynitrile Lyase Demand Analysis

Established pharmaceutical biocatalysis infrastructure and enzyme production capabilities at c-LEcta and Evonik position Germany as a primary supply center for hydroxynitrile lyase enzymes serving European pharmaceutical manufacturing. EU green chemistry regulatory support and established academic-industry collaboration in enzyme engineering at German research institutions provide the innovation foundation for continued market leadership in pharmaceutical biocatalysis technology.

• c-LEcta and Evonik enzyme production capabilities position Germany as a European supply hub for pharmaceutical-grade hydroxynitrile lyase enzymes.
• EU green chemistry regulations and German academic-industry enzyme engineering collaboration support continued biocatalysis technology leadership.

Competitive Benchmarking and Company Positioning

Hydroxynitrile Lyase Market Analysis By Company

• Novozymes (DSM-Firmenich) and Codexis hold leading positions through comprehensive enzyme engineering platforms, established pharmaceutical customer relationships, and broad biocatalyst portfolios that include hydroxynitrile lyase variants alongside complementary enzyme classes for multi-step synthesis.
• c-LEcta and Evonik Industries compete through focused pharmaceutical enzyme production, European manufacturing capability, and application development expertise for chiral intermediate synthesis programs.
• Enzyme engineering platform capability and pharmaceutical regulatory documentation are the primary competitive differentiators, as pharmaceutical manufacturers require enzyme suppliers with demonstrated cGMP production, stability documentation, and process development support.

The competitive landscape is concentrated among a small number of specialized enzyme producers and engineering platform companies. Novozymes (DSM-Firmenich) and Codexis compete through broad biocatalysis platforms, AI-driven enzyme engineering, and established pharmaceutical customer bases. These companies provide complete solutions from enzyme screening through process development and manufacturing-scale supply.

c-LEcta, Evonik Industries, and Enzymaster compete through focused enzyme development and production capabilities serving pharmaceutical and fine chemical customers. Almac Group, Johnson Matthey, and BASF provide biocatalytic services and enzyme supply as components of broader pharmaceutical chemistry platforms.

Strategic priorities include accelerating AI-driven enzyme engineering to reduce development timelines, expanding cGMP enzyme production capacity, building pharmaceutical regulatory documentation, and supporting CDMO adoption of biocatalytic processes through licensing and technical transfer programs.

Key Companies in the Hydroxynitrile Lyase Market

• Novozymes (DSM-Firmenich) and Codexis Inc. are among the leading participants in the hydroxynitrile lyase market, supported by comprehensive enzyme engineering platforms and established pharmaceutical industry relationships.
• c-LEcta GmbH, Evonik Industries AG, and Enzymaster (Ningbo) hold focused positions through pharmaceutical enzyme production and application development expertise.
• BASF SE, Johnson Matthey, Almac Group, and Enzymicals AG compete through broader pharmaceutical chemistry platforms that include biocatalytic services alongside chemical catalysis and process development offerings.

Recent Industry Developments

• Codexis, Engineered Enzyme Platform Expansion for Pharmaceutical Biocatalysis (2025)
  • Codexis expanded its engineered enzyme platform including hydroxynitrile lyase variants with improved activity and stability for pharmaceutical intermediate production, supporting growing demand from manufacturers adopting biocatalytic synthesis at commercial scale.
• c-LEcta, Recombinant Enzyme Production Scale-up in Leipzig, Germany (2025)
  • c-LEcta advanced recombinant enzyme production scale-up at its Leipzig facility, supporting growing pharmaceutical and fine chemical demand for hydroxynitrile lyase and other biocatalytic enzymes for enantioselective synthesis programs.
• Novozymes and DSM-Firmenich, Biocatalysis Portfolio Integration (2025 to 2026)
  • The integration of Novozymes and DSM-Firmenich enzyme and biocatalysis portfolios consolidated capabilities in industrial enzyme production and pharmaceutical application support, strengthening market positioning in specialty enzyme supply for chiral intermediate manufacturing.

Leading Companies Shaping the Hydroxynitrile Lyase Market

• Novozymes A/S (DSM-Firmenich)
• c-LEcta GmbH
• Codexis Inc.
• Enzymaster (Ningbo)
• Evonik Industries AG
• BASF SE
• Johnson Matthey
• Almac Group
• Enzymicals AG
• DSM-Firmenich

Sources and Research References

• Codexis Inc. Enzyme engineering platform documentation and pharmaceutical biocatalysis applications.
• c-LEcta GmbH. Recombinant enzyme production and pharmaceutical enzyme supply documentation.
• Novozymes (DSM-Firmenich). Industrial enzyme portfolio and biocatalysis capability integration updates.
• FDA. Green chemistry guidance for pharmaceutical manufacturing process development.
• Primary interviews with enzyme producers, pharmaceutical manufacturers, CDMOs, and process development organizations.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the Hydroxynitrile Lyase Market?
• How fast is the market expected to grow between 2026 and 2036?
• Which product type leads by 2026?
• Which end-use segment accounts for the highest demand?
• What factors drive pharmaceutical adoption of hydroxynitrile lyases?
• How is AI-driven enzyme engineering influencing the market?
• Why are China and India the fastest-growing markets?
• How are CDMOs supporting biocatalysis adoption?
• Which countries show the fastest growth through 2036?
• Who are the key companies?
• How does Fact.MR validate the forecast?

Hydroxynitrile Lyase Market Definition

The Hydroxynitrile Lyase Market covers enzymes that catalyze the enantioselective addition of hydrogen cyanide to aldehydes and ketones to form chiral cyanohydrins, used as biocatalysts in pharmaceutical intermediate, fine chemical, and agrochemical production.

Hydroxynitrile Lyase Market Inclusions

• The scope covers global and regional market size and forecasts for 2026 to 2036 across product type, end use, formulation type, and region.
• It includes recombinant, plant-extracted, immobilized, and engineered variant hydroxynitrile lyase products for pharmaceutical, fine chemical, and agrochemical applications.
• The report covers enzyme engineering trends, biocatalysis technology developments, and the competitive landscape of leading enzyme producers.

Hydroxynitrile Lyase Market Exclusions

• The scope excludes general-purpose industrial enzymes not classified as hydroxynitrile lyases, including lipases, proteases, and transaminases used in other biocatalytic applications.
• It excludes chemical catalysts, chiral resolution reagents, and non-enzymatic asymmetric synthesis technologies.
• The report excludes downstream finished pharmaceutical products and completed fine chemical intermediates.

Hydroxynitrile Lyase Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 75+ secondary sources and benchmarks 35+ company product portfolios.
• Market sizing covers 30+ countries through a demand-side model, supported by top-down validation.
• Key inputs include pharmaceutical intermediate production data, biocatalysis adoption rates, enzyme engineering technology progress, and CDMO capability investment tracking.
• Primary validation includes 20+ interviews across enzyme producers, pharmaceutical manufacturers, CDMOs, and process development organizations.